LifeMD, Inc. (NASDAQ:LFMD) Receives $13.17 Consensus Target Price from Brokerages

LifeMD, Inc. (NASDAQ:LFMDGet Free Report) has been assigned an average rating of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $13.1667.

LFMD has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of LifeMD in a report on Wednesday, October 8th. Lake Street Capital cut their target price on shares of LifeMD from $18.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. KeyCorp decreased their price target on shares of LifeMD from $14.00 to $12.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 6th. HC Wainwright cut their price objective on shares of LifeMD from $14.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. Finally, Wall Street Zen lowered shares of LifeMD from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd.

Get Our Latest Analysis on LFMD

LifeMD Stock Up 2.3%

Shares of NASDAQ LFMD opened at $6.22 on Friday. The firm’s 50-day moving average is $6.35 and its two-hundred day moving average is $8.70. The company has a market capitalization of $294.95 million, a PE ratio of -29.62 and a beta of 1.67. LifeMD has a 12-month low of $3.99 and a 12-month high of $15.84. The company has a debt-to-equity ratio of 9.21, a current ratio of 0.77 and a quick ratio of 0.72.

Insider Activity at LifeMD

In related news, insider Nicholas P. Alvarez sold 75,000 shares of the company’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $5.92, for a total value of $444,000.00. Following the completion of the transaction, the insider directly owned 605,000 shares in the company, valued at approximately $3,581,600. This represents a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 18.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Mirador Capital Partners LP boosted its position in shares of LifeMD by 24.9% in the third quarter. Mirador Capital Partners LP now owns 193,540 shares of the company’s stock worth $1,314,000 after acquiring an additional 38,575 shares during the last quarter. Hudson Bay Capital Management LP acquired a new position in LifeMD during the second quarter worth approximately $153,000. Tower Research Capital LLC TRC raised its stake in LifeMD by 110.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after purchasing an additional 2,452 shares during the period. Oxford Asset Management LLP acquired a new position in shares of LifeMD in the 2nd quarter valued at $168,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of LifeMD by 351.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 216,898 shares of the company’s stock worth $2,954,000 after buying an additional 168,871 shares during the last quarter. Institutional investors and hedge funds own 35.52% of the company’s stock.

LifeMD Company Profile

(Get Free Report)

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.

Read More

Analyst Recommendations for LifeMD (NASDAQ:LFMD)

Receive News & Ratings for LifeMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeMD and related companies with MarketBeat.com's FREE daily email newsletter.